|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation.
|
12852432 |
2003 |
|
Presenile dementia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We explored how levels of endocytic proteins, APP, its metabolites, secretase enzymes, and tau varied with age in cortical brain samples from men of three age ranges (young [20-30], middle aged [45-55], and old [70-90]) with no symptoms of dementia.
|
28655199 |
2018 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Trisomy 21 and the consequent extra copy of the amyloid precursor protein (APP) gene and increased beta-amyloid (Aβ) peptide production underlie the universal development of Alzheimer's disease (AD) pathology and high risk of AD dementia in people with Down syndrome (DS).
|
26651340 |
2016 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease.
|
16266835 |
2006 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we exposed an AD-relevant mouse model (APP/PS1 KI) to chronic intermittent hypoxia (IH) (an experimental model of sleep apnea) to begin to describe one of the potential mechanisms by which SDB could increase the risk of dementia.
|
30529693 |
2019 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.
|
21209907 |
2010 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have used the powerful technique of denaturing gradient gel electrophoresis to screen for mutations in exons 7, 16 and 17 of the APP gene in a cohort of 105 patients with presenile dementia of the Alzheimer type and 71 patients with autopsy-confirmed senile Alzheimer's disease.
|
8321254 |
1993 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Early effects of aluminum chloride on beta-secretase mRNA expression in a neuronal model of beta-amyloid toxicity.
|
20111991 |
2010 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
An elderly man with phenotypic DS and partial trisomy of chromosome 21 (PT21) lacked triplication of APP affording an opportunity to study the role of this gene in the pathogenesis of dementia.
|
27983553 |
2017 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The E693Delta mutation within the amyloid precursor protein (APP) has been suggested to cause dementia via the enhanced formation of synaptotoxic amyloid beta (Abeta) oligomers.
|
19164507 |
2009 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
High performance plasma amyloid-β biomarkers for Alzheimer's disease.
|
29420472 |
2018 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant component of memory loss in APP transgenic mice is apparently caused by soluble A Beta assemblies, but whether and how much of the dementia within individuals afflicted with AD is caused by these A Beta species is unclear.
|
11773429 |
2002 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
|
15590663 |
2005 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The dementia in patients with the APP692 mutation was compatible with Alzheimer's disease both clinically and neuropathologically.
|
11004129 |
2000 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ischemic lesions are characteristic of several hereditary CAA syndromes, including a recently described mutation of the amyloid precursor protein associated with dementia (but not hemorrhagic stroke) in an Iowa family.
|
11901242 |
2002 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We suggest instead that APP normally functions in the brain as a cell surface signaling molecule, and that a disruption of this normal function of APP is at least one cause of the neurodegeneration and consequent dementia in AD.
|
11119687 |
2000 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three members of an Italian family with autosomal dominant dementia and multiple strokes had the A713T mutation of the APP gene.
|
15365148 |
2004 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The evidence that a pathogenic APP mutation causes an early enhancement of BAD-Glu suggests that alterations of BACE1 processing of APP in glutamatergic synaptic vesicles could contribute to dementia.
|
31496118 |
2019 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the precise mechanism remains to be elucidated, our data suggest a possible role for APP in modifying the PD phenotype as well as a general contribution of genetic factors to the development of dementia in individuals with PD.
|
25604855 |
2015 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia.
|
22170863 |
2012 |
|
Presenile dementia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conclude that miR-195 may play a key role in determining dementia susceptibility in 2VO rats by regulating APP and BACE1 expression at the post-transcriptional level, and exogenous complement of miR-195 may be a potentially valuable anti-dementia approach.
|
23447608 |
2013 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of DSCAM in Down syndrome (DS) may be involved in the pathogenesis of mental retardation through an inhibitory action on synaptogenesis/neurite outgrowth, and in the precocious dementia associated with an amyloid precursor protein (APP) dosage effect with enhanced plaque formation.
|
21241773 |
2011 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the association between cognitive function and several serum miRNAs levels related to amyloid precursor protein (APP) proteolysis in a Japanese general population who had never been diagnosed with dementia.
|
30802839 |
2020 |
|
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We screened 37 AD, 8 mild cognitive impairment (MCI), 3 AD and CVD (cerebrovascular disease), 3 MCI and CVD, 8 frontotemporal dementia (FTD) and 2 progressive supranuclear palsy (PSP) patients, and 28 normal controls (NCs).We sequenced PSEN1, PSEN2 and APP (EOAD risk factors), as well as MAPT, GRN and TARDBP for all cases and NCs, and analysed the APOE, CLU, CR1 and PICALM genotypes as well as the MAPT and ACE haplotypes (LOAD risk factors) for the AD (n = 37) and AD + MCI (n = 45) cases and NCs (n = 28).We identified variants in PSEN1, PSEN2 and TARDBP across a range of phenotypes (AD, AD and CVD, FTD and PSP), suggesting that screening of all known candidate genes of Alzheimer's and non-Alzheimer's forms of dementias in all dementia cases might be warranted.
|
26159191 |
2015 |